Relationship of dose- and time-dependent corticosteroid responses to receptor turnover

Inhaled Steroids in Asthma: Optimizing Effects in the Airways

Volumn , Issue , 2016, Pages 95-112

  Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012738384     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780203908532-7     Document Type: Chapter

References (39)

1. Jusko WJ, Ludwig EA. Corticosteroids. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA: Applied Therapeutics Inc., 1994: 1-34.
2. Kong A-N, Ludwig EA, Slaughter RL, DiStefano PM, De Masi J, Middleton Jr E, Jusko WJ. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther 1989; 46:616-628.
3. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21:457-478.
4. Wald JA, Salazar DE, Cheng H, Jusko WJ. Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J Pharmacokinet Biopharm 1991; 19:521-536.
5. Fisher LE, Ludwig EA, Jusko WJ. Pharmacoimmunodynamics of methylprednisolone:trafficking of helper T lymphocytes. J Pharmacokinet Biopharm 1992; 20:319-331.
6. Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991; 50:536-549.
7. Chakraborty A, Krzyzanski W, Jusko WJ. Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J Pharmacokinet Biopharm 1999; 27:23-43.
8. Reiss WG, Slaughter RL, Ludwig EA, Middleton Jr E, Jusko WJ. Steroid dosesparing:pharmacodynamic responses to single versus divided doses of methylprednisolone in man. J Allergy Clin Immunol 1990; 85:1058-1066.
9. Gobburu J, Jusko WJ. Role of dosage regimen in controlling indirect pharmacodynamic responses. Advanced Drug Del Rev 1998; 33:221-233.
10. Mishina EV, Straubinger RM, Pyszczynski NA, Jusko WJ. Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. Pharm Res 1993; 10:1402-1410.
11. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283-286.
12. Auphan N, Didonato JA, Rosette C, Helmberg A, Karn M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of 1κB synthesis. Science 1995; 270:286-288.
13. Metcalfe SM, Richards FM. Cyclosporine, FK506, and rapamycin: some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. Transplantation 1990; 49:798-802.
14. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17:660-666.
15. Ferron GM, Pyszczynski NA, Jusko WJ. Gender-related assessment of cyclosporine/ prednisolone/sirolimus interactions in three human lymphocyte proliferation assays. Transplantation 1998; 65:1203-1209.
16. Oakley RM, Cidlowski JA. Homologous down regulation of the glucocorticoid receptor:the molecular machinery. Crit Rev Eukary Gen Expr 1993; 3:63-88.
17. Tingley DW. Evolutions: steroid-hormone receptor signaling. J NIH Res 1996; 8:81-88.
18. Vamvakopoulos NO. Tissue-specific expression of heat shock proteins 70 and 90: potential implication for differential sensitivity of tissues to glucocorticoids. Molec Cell Endocrinol 1993; 98:49-54.
19. Czar MJ, Owens-Grillo JK, Dittmar KD, Hutchison KA, Zacharek AM, Leach KL, Deibel Jr MR, Pratt WB. Characterization of the protein-protein interactions determining the shock protein (hsp90.hsp70, hsp56) heterocomplex. J Biol Chem 1994; 269:11155-11161.
20. Orti E, Hu LM, Munck A. Kinetics of glucocorticoid receptor phosphorylation in intact cells. Evidence for hormone-induced hyperphosphorylation after activation and recycling of hyperphosphorylated receptors. J Biol Chem 1993; 268:7779-7784.
21. Segard-Maurel I, Rajkowski K, Jibard N, Schweizer-Groyer G, Baulieu E-E, Cadepond F. Glucocorticoid receptor dimerization investigated by analysis of receptor binding to glucocorticoid responsive elements using a monomer-dimer equilibrium model. Biochemistry 1996; 35:1634-1642.
22. Cooney AJ, Tsai SY. Nuclear receptor-DNA interactions. In: Tsai M-J, O’Malley BW, eds. Mechanism of Steroid Hormone Regulation of Gene Transcription. R. G. Landes Company, 1994:25-59.
23. Lewin B. Regulation of transcription: factors that activate the basal apparatus. In:Genes V. Oxford University Press, 1994:879-909.
24. Lewin B. Control at initiation: RNA polymerase-promotor interactions. In: Genes V. Oxford University Press, 1994:377-411.
25. Lewin B. The assembly line for protein synthesis. In: Genes V. Oxford University Press, 1994:163-195.
26. Dong Y, Poellinger L, Gustafsson J-A, Okret S. Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanism. Mol Endo 1988; 2:1256-1264.
27. Vedeckis WV, Ali M, Allen HR. Regulation of glucocorticoid receptor protein and mRNA levels. Cancer Res 1989; 49:2295s-2320s.
28. Bernstein P, Peltz SW, Ross J. The poly(A)-poly(A)-binding protein complex is a major determination of mRNA stability in vitro. Molec Cell Biol 1989; 9:659-670.
29. Munck A, Holbrook NJ. Glucocorticoid-receptor complexes in rat thymus cells:Rapid kinetic behavior and a cyclic model. J Biol Chem 1984; 259:820-831.
30. Boudinot FD, D’Ambrosio R, Jusko WJ. Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokin Biopharm. 1986; 14:469-493.
31. Nichols AI, Boudinot FD, Jusko WJ. Second generation model for prednisolone pharmacodynamics in the rat. J Pharmacokin Biopharm. 1989; 17:209-227.
32. Haughey DB, Jusko WJ. Receptor-mediated methylprednisolone pharmacodynamics in rats: steroid-induced receptor down-regulation. J Pharmacokin Biopharm 1992; 19:333-355.
33. DuBois DC, Almon RR, Jusko WJ. Molar quantification of specific messenger ribonucleic acid expression in Northern hybridization using cRNA standards. Analytical Biochem 1993; 210:140-144.
34. Xu Z-X, Sun Y-N, DuBois DC, Almon RR, Jusko WJ. Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokin Biopharm 1995; 23:163-181.
35. Sun Y-N, DuBois DC, Almon RR, Jusko WJ. Fourth-generation model for corticosteroid pharmacodynamics: A model for methylprednisolone effects on receptor/genemediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokin Biopharm 1998; 26:289-316.
36. Sun Y-N, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. Dose-dependence and repeated-dose studies for receptor/gene mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokin Biopharm 1998; 26:619-648.
37. Sun Y-N, McKay LI, DuBois DC, Jusko WJ, Almon RR. Pharmacokinetic-pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a receptor/gene-mediated mechanism. J Pharmacol Exp Ther 1999; 288:720-728.
38. Sun Y-N, Jusko WJ. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 1998; 87:732-737.
39. Nichols AI, Jusko WJ. Receptor-mediated prednisolone pharmacodynamics in rats:model verification using a dose-sparing regimen. J Pharmacokin Biopharm 1990; 18:189-208.